ML327
ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT) .
Product Specifications
CAS Number
1883510-31-3
UNSPSC
12352005
Hazard Statement
H302
Target
Autophagy; c-Myc
Type
Reference compound
Related Pathways
Apoptosis; Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ML327.html
Purity
98.02
Solubility
DMSO : 32 mg/mL (ultrasonic; warming)
Smiles
O=C(C1=CC=CNC1=O)NCCCNC(C2=NOC(C3=CC=CC=C3)=C2)=O
Molecular Formula
C19H18N4O4
Molecular Weight
366.37
Precautions
H302
References & Citations
[1]Rellinger EJ, et al. Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. Oncotarget. 2017 Jul 20;8 (53) :91040-91051.|[2]An H, et al. Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.Oncotarget. 2015 Sep 8;6 (26) :22934-48.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC472745-100 1x 100 µL
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2745), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNUB2111-500 1x 500 µL
MSH6 (DNA Mismatch Repair Protein) (MSH6/2111), 0.2mg/mL
Sign In for Pricing
View Details 
